Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes.

Concetta IraceAntonio CutruzzolàAnnamaria NuzziRoberta AssaloniBarbara BrunatoDario PitoccoLinda TartaglioneSergio Di MolfettaAngelo CignarelliLuigi LaviolaGiuseppe CitroElisabetta LovatiAgostino GnassoKatherine S TwedenFrancine R Kaufman

Published in: Diabetes, obesity & metabolism (2020)

Real-world clinical use of the Eversense CGM System for 180 days was associated with significant improvements in HbA1c and CGM metrics among adults with type 1 diabetes. The study is registered on clinicaltrials.gov (NCT04160156).

Keyphrases

type diabetes
metabolic syndrome
blood pressure
blood glucose
weight loss